When Will Sensus Healthcare, Inc. (NASDAQ:SRTS) Turn A Profit?

7/8/2019 12:36:48 PM

Sensus Healthcare, Inc.'s (NASDAQ:SRTS): Sensus Healthcare, Inc. manufactures and markets superficial radiation...

Edited Transcript of SRTS earnings conference call or presentation 9-May-19 8:30pm GMT

6/12/2019 2:56:32 PM

Q1 2019 Sensus Healthcare Inc Earnings Call

Sensus Healthcare to Present at the Raymond James Inaugural Life Sciences and MedTech Conference

6/10/2019 3:00:00 PM

BOCA RATON, Fla., June 10, 2019 -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both.

Sensus Healthcare to Present at the 20th Annual B. Riley FBR Investor Conference

5/15/2019 12:30:00 PM

BOCA RATON, Fla. , May 15, 2019 /PRNewswire/ --  Sensus Healthcare, Inc.  (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological ...

Sensus Healthcare Reports First Quarter 2019 Financial Results

5/9/2019 8:02:00 PM

- Premier, Inc. adds SRT to its group purchasing contracts - Ships second Sculptura™ system to Rabin Medical Center in Israel - Reaffirms expectations for double-digit full-year revenue growth - Conference ...

Sensus Healthcare Awarded Brachytherapy Products Agreement with Premier

5/8/2019 12:30:00 PM

BOCA RATON, Fla., May 8, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in novel radiation oncology technologies and solutions, has been awarded a group purchasing agreement for Brachytherapy Products with Premier. Effective August 1, 2019, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Sensus' SRT-100™ Superficial Radiation Therapy systems. "Premier is a well-established and respected organization," said Joe Sardano, CEO, Sensus Healthcare.

Does The Data Make Sensus Healthcare, Inc. (NASDAQ:SRTS) An Attractive Investment?

5/7/2019 6:56:46 PM

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Sensus Healthcare, Inc. (NASDAQ:SRTS) is a stock with outstanding fundamental characteristic...

Sensus Healthcare to Host First Quarter 2019 Financial Results and Business Update Conference Call on May 9, 2019

4/25/2019 8:00:00 PM

BOCA RATON, Fla. , April 25, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological ...

Sensus Healthcare Signs R&D Agreement to Collaborate with Perelman School of Medicine at the University of Pennsylvania on World's First Sculptura™ Intraoperative Radiation Therapy System

4/24/2019 12:30:00 PM

BOCA RATON, Fla., April 24, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in novel radiation oncology technologies and solutions, today announced that the Company has signed a research and development agreement with the Perelman School of Medicine at the University of Pennsylvania to collaborate with the radiation oncology department on clinical research and development for Sensus' Sculptura™ robotic intraoperative radiation therapy (IORT) system.

Five-Year Retrospective Study Shows 98.9 Percent Cure Rate for Non-Melanoma Skin Cancer Patients Treated with Sensus Healthcare's Superficial Radiation Therapy

4/23/2019 12:30:00 PM

BOCA RATON, Fla., April 23, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in non-invasive treatments for both oncological and non-oncological conditions, announced today topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation Therapy (SRT) (ClinicalTrials.gov Identifier: NCT03693937).

Sensus Healthcare Inc (SRTSU) Files 10-K for the Fiscal Year Ended on December 31, 2018

3/16/2019 11:48:07 AM

Warning! GuruFocus has detected 2 Warning Signs with SRTSU. For the last quarter Sensus Healthcare Inc reported a revenue of $8.08 million, compared with the revenue of $6.47 million during the same period a year ago. For the last five years Sensus Healthcare Inc had an average revenue growth rate of 28.5% a year.

Sensus Healthcare to Present at the 31st Annual ROTH Conference

3/13/2019 12:00:00 PM

BOCA RATON, Fla. , March 13, 2019 /PRNewswire/ --  Sensus Healthcare, Inc.  (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological ...

Sensus Healthcare Launches SRT University, an Online Portal to Support Physicians

3/12/2019 12:30:00 PM

BOCA RATON, Fla., March 12, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today the launch of SRT University, an online portal to support physicians using Sensus devices and technology. The new online portal provides physicians and their staff access to Sensus' depository of information related to superficial radiation therapy (SRT) and intraoperative radiotherapy (IORT). "As we expand our course catalog, we strive to provide our physicians access to tools and educational materials that benefit their practice and positively effect patient outcomes," said Kal Fishman, Sensus Healthcare Chief Technology Officer.

Sensus Healthcare Appoints Dr. Ziv Karni as Chief Scientific Officer

2/28/2019 1:00:00 PM

BOCA RATON, Fla., Feb. 28, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the Company has appointed Dr. Ziv Karni to the role of Chief Scientific Officer, effective immediately. Dr. Karni, a pioneer in medical technology research and development, has more than 30 years of experience in the development and sales of medical and aesthetic technologies.

Is Sensus Healthcare, Inc. (NASDAQ:SRTS) A Cash Cow?

2/27/2019 3:21:54 PM

Two important questions to ask before you buy Sensus Healthcare, Inc. (NASDAQ:SRTS) is, how it makes money and how it spends its cash. After investment, what’s left over is whatRead More...

U.S. FDA Grants Market Clearance to Sensus Healthcare's New Sculptura™ Radiation Oncology System

2/26/2019 1:00:00 PM

BOCA RATON, Fla., Feb. 26, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted market clearance for the Company's groundbreaking Sculptura™ radiation oncology system. A single treatment during surgery, Sculptura™ can provide cancer patients and physicians a single radiation treatment at the point of surgery. "With the creation of Sculptura™, Sensus is pioneering a new whole approach to radiation oncology that will ultimately benefit both patients and the medical community at large," said Joe Sardano, Sensus Healthcare CEO.

Edited Transcript of SRTS earnings conference call or presentation 14-Feb-19 9:30pm GMT

2/22/2019 4:32:27 PM

Q4 2018 Sensus Healthcare Inc Earnings Call

Sensus Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth

2/14/2019 9:02:00 PM

Shipped 27 systems during the quarter including 15 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. , Feb. 14, 2019 /PRNewswire/ --  Sensus Healthcare, Inc. ...

Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radiation Therapy to Treat Non-Melanoma Skin Cancers and Keloids

2/14/2019 1:30:00 PM

Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment.

Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare's SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities

2/12/2019 1:45:00 PM

BOCA RATON, Fla., Feb. 12, 2019 /PRNewswire/ -- Sensus Healthcare, Inc. (SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), announces the publication of a new retrospective study that showed a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal and squamous cell carcinomas on their lower extremities with Sensus' SRT-100TM Superficial Radiation Therapy.